Remote-controlled CAR-T cells use venetoclax to disengage from tumors
Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their promise, CAR-T cells do ...
Feb 19, 2026
0
0









